ATRANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Atara Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.96−0.22 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $134.70M
- P/E (TTM)
- 3.5
- Dividend yield
- –
Share price
−$5.85 (−39.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Atara Biotherapeutics, Inc. saw revenue fall 96.7% to $6.19M over the twelve months to Jun 30, 2026. Operating income fell 277.0% to -$14.23M, moving the operating margin from 4.3% to -229.7%. Free cash flow was -$50.94M.
Revenue
$6.19M
-96.7% vs. a year earlier
Operating income
-$14.23M
-277.0% vs. a year earlier
Free cash flow
-$50.94M
FY2025
EPS, diluted
$2.57
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $134.70M
- P/E ratio
- 3.5
- Price to sales
- 21.75
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -37.82%
Fundamentals
- Revenue
- $6.19M
- Net income
- -$16.69M
- EPS, diluted
- $2.57
- Free cash flow
- -$50.94M
- Book value per share
- -$2.46
- Diluted shares
- 15M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$6.19M-96.7% YoY
Operating income
-$14.23M-277.0% YoY
Net income
-$16.69M-388.0% YoY
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months